ClinicalTrials.gg
Status unknownNCT03849768Updated Jan 20, 2023Results posted

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

A Phase 3 interventional study of HS-10296 and Gefitinib in Non Small Cell Lung Cancer, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-20.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
429
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 18 under way, 7 of them phase 3. aumolertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 29
429 · median 150
Started
2019
with 1 other
Phase 3
11 of 29
4 open now
Registered
2nd of 29
by date
Lead sponsor
8 of 29
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, controlled, double-blind, multicenter, phase III clinical study.

Read the detailed description

This is a randomized, controlled, double-blind, multicenter, phase III clinical trial, evaluating the efficacy and safety of HS-10296 compared to gefitinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor sensitizing mutations (EGFRm+) who have not received systemic therapy. Patients are randomly assigned to an HS-10296 treatment group or a gefitinib treatment group at a ratio of 1:1 and receive a once-daily oral dose of HS-10296 or gefitinib, in order to compare the efficacy and safety of the two different treatment regimens.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Inclusion Criteria:

Any patient who meets all of the following inclusion criteria will qualify for entry into the study:

  1. Provision of prior to any study specific procedures, sampling and analyses.
  2. Male or female, age at least 18 years.
  3. confirmed locally advanced or NSCLC (e.g. this may occur systemic recurrence after prior surgery for early stage disease or patients may be newly diagnosed with stage IIIB/IV disease). Patients must be treatment-naïve for locally advanced or metastatic NSCLC. Prior and neo-adjuvant therapy is permitted (chemotherapy, radiotherapy, agents) provided all other entry criteria are satisfied.
  4. The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either or in combination with other EGFR mutations assessed by central testing using tumour tissue sample or blood sample.
  5. A equal to 0-1 with no deterioration over the previous 2 weeks and a minimum of 12 weeks.
  6. At least 1 lesion that has not previously been irradiated, that has not been chosen for during the study screening period, and that can be accurately measured at Baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), whichever is suitable for accurately repeated measurements. If only one exists, it is acceptable to be used (as a target lesion) as long as it has not been previously irradiated and baseline tumour assessment scans are done at least 14days afar the screening biopsy is performed.
  7. Females should be using adequate measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have a negative pregnancy test prior to start of dosing if of or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at Screening:

    1. defined as age more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
    2. Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory.
    3. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.
  8. Male patients should be willing to use barrier contraception (i.e., condoms).
  9. For inclusion in study, patient must provide a written informed consent.

    -

Exclusion Criteria: Exclusion Criteria:

Any patient who meets any of the following exclusion criteria will not qualify for entry into the study:

  1. Treatment with any of the following:

    1. Prior treatment with systemic anti-cancer therapy for locally advancer or metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.
    2. Prior treatment with an EGFR TKI.
    3. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug.
    4. Radiotherapy with a limited field of radiation for palliation within 4 week of the first dose of study drug, with the exception of patients receiving radiation to > 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
    5. Medications that are predominantly strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug.
  2. Any concurrent and/or other active that has required treatment within 2 years of first dose of study drug.
  3. Any unresolved toxicities from prior therapy greater than (CTCAE) Grade 1 at the time of starting study treatment, with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
  4. Spinal cord compression or unless asymptomatic, stable, and not requiring for at least 2 weeks prior to start of study treatment.
  5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension or active bleeding diatheses, which, in the Investigator's opinion, makes it undesirable for the patient to participate in the trial OR which would jeopardize compliance with the protocol such as active infection. Screening for chronic conditions is not required.
  6. nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study drug, or previous significant bowel resection that would preclude adequate absorption of HS 10296.
  7. Any of the following cardiac criteria:

    1. Mean resting interval (QTc) > 470 ms obtained from 3 (ECGs), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
    2. Any abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 ms).
    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
    4. (LVEF) ≤ 40%.
  8. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
  9. Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values:

    1. (ANC) \<1.5×109 / L
    2. count \<100×109 / L
    3. \<90 g/L(\<9 g/dL)
    4. > 2.5 × (ULN) if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases.
    5. Aspartate aminotransferase (AST) > 2.5 × ULN if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases.
    6. Total (TBL) > 1.5 × ULN if no liver metastases or > 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
    7. Creatinine > 1.5 × ULN concurrent with \< 50 mL/min (measured or calculated by the Cockcroft-Gault equation); confirmation of creatinine clearance is only required when creatinine is > 1.5 × ULN.
  10. Women who are breastfeeding or have a positive urine or serum pregnancy test at the Screening Visit.
  11. History of to any active or inactive ingredient of HS 10296 or to drugs with a similar chemical structure or class to HS 10296.
  12. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  13. Any severe and uncontrolled ocular disease that may, in the ophthalmologist's opinion, present a specific risk to the patient's safety.
  14. Any disease or condition that, in the opinion of the Investigator, would compromise the safety of the patient or interfere with study assessments.

    -

Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
429 participants (actual)

Study arms

  • Experimental
    HS-10296

    110mg PO once daily

    Drug: HS-10296

  • Active comparator
    Gefitinib

    250mg PO once daily

    Drug: Gefitinib

Interventions

  • Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

    Also known as: Investigational Product

  • Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

    Also known as: Comparator Product

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of first dose until the date of radiological disease progression or until death due to any cause, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by investigators. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, approximately 2 years.

Secondary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR)

    ORR is defined as the percentage of patients who have at least 1 response of CR or PR prior to any evidence of progression. Target lesions and assessed by CT per RECIST v1.1 (Complete Response(CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.).

    Time frame: From baseline, then every 6 weeks, until disease progression or discontinuation from study.(up to 24 months)

  2. Assess the Anti-tumor Activity: Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression assessed up to 24 months.

    Time frame: From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)

  3. Assess the Anti-tumor Activity: Disease Control Rate (DCR)

    The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD assessed up to 24 months.

    Time frame: From baseline, then every 6 weeks, until disease progression or discontinuation from study.

  4. Assess the Anti-tumor Activity: Depth of Response (DepOR)

    DepOR is defined as the percentage change in tumor shrinkage, based on longest diameter or reconstructed volume, observed at the lowest point (nadir) compared with baseline.

    Time frame: From baseline, then every 6 weeks, until disease progression or discontinuation from study.(up to 24 months)

  5. Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs)

    Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization.

    Time frame: Continuously throughout the study until 28 days after HS-10296 discontinuation.From first dose of study drug up to 28 days after last dose of study drug taken (up to data cut-off (15 Jan 2021)),approximately 2 years.

  6. Number of Participants With Dose Interruptions

    Participants had at least one delay in planned treatment due to treatment emergent adverse events.

    Time frame: From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)

  7. Number of Participants With Dose Reductions

    Participants had at least one reduction in planned treatment dosage due to treatment emergent adverse events. Every participant took 2 pills of HS -10296 + 1 pill of placebo(experimental arm) or 2pills of placebo + 1pill of Gefitinib (control arm). When a dose reduction was decided by INV, the set of "2 pills of placebo" was decreased resulting in no reduction of active compound in control arm, compliance with dose modification for AEs in Gefitinib's label which includes interruption, discontinuation but reduction.

    Time frame: From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)

07

Results

Posted Jan 20, 2023

Participant flow

A total of 429 participants were randomized to at 53 study sites.

Participant flow — Overall Study
MilestoneHS-10296Gefitinib
Started214215
Completed121181
Not completed9334

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from the date of first dose until the date of radiological disease progression or until death due to any cause, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by investigators. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, approximately 2 years.
Reported as:
Median · months
Progression Free Survival (PFS)
monthsHS-10296Gefitinib
Progression Free Survival (PFS)19.3 (17.8 to 20.8)9.9 (8.3 to 12.6)
SecondaryPercentage of Participants With Objective Response Rate (ORR)

ORR is defined as the percentage of patients who have at least 1 response of CR or PR prior to any evidence of progression. Target lesions and assessed by CT per RECIST v1.1 (Complete Response(CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.).

Time frame:
From baseline, then every 6 weeks, until disease progression or discontinuation from study.(up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response Rate (ORR)
percentage of participantsHS-10296Gefitinib
Percentage of Participants With Objective Response Rate (ORR)73.8 (67.4 to 79.6)72.1 (65.6 to 78.0)
SecondaryAssess the Anti-tumor Activity: Duration of Response (DoR)

DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression assessed up to 24 months.

Time frame:
From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)
Reported as:
Median · months
Assess the Anti-tumor Activity: Duration of Response (DoR)
monthsHS-10296Gefitinib
Assess the Anti-tumor Activity: Duration of Response (DoR)18.1 (15.2 to NA)8.3 (6.9 to 11.1)
SecondaryAssess the Anti-tumor Activity: Disease Control Rate (DCR)

The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD assessed up to 24 months.

Time frame:
From baseline, then every 6 weeks, until disease progression or discontinuation from study.
Reported as:
Number · percentage
Assess the Anti-tumor Activity: Disease Control Rate (DCR)
percentageHS-10296Gefitinib
Assess the Anti-tumor Activity: Disease Control Rate (DCR)93.0 (88.7 to 96.0)96.7 (93.4 to 98.7)
SecondaryAssess the Anti-tumor Activity: Depth of Response (DepOR)

DepOR is defined as the percentage change in tumor shrinkage, based on longest diameter or reconstructed volume, observed at the lowest point (nadir) compared with baseline.

Time frame:
From baseline, then every 6 weeks, until disease progression or discontinuation from study.(up to 24 months)
Reported as:
Mean · percentage of change from baseline
Assess the Anti-tumor Activity: Depth of Response (DepOR)
percentage of change from baselineHS-10296Gefitinib
Assess the Anti-tumor Activity: Depth of Response (DepOR)-44.95 ± 21.961-41.95 ± 19.966
SecondaryNumber of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs)

Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization.

Time frame:
Continuously throughout the study until 28 days after HS-10296 discontinuation.From first dose of study drug up to 28 days after last dose of study drug taken (up to data cut-off (15 Jan 2021)),approximately 2 years.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs)
ParticipantsHS-10296Gefitinib
Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs)211213
SecondaryNumber of Participants With Dose Interruptions

Participants had at least one delay in planned treatment due to treatment emergent adverse events.

Time frame:
From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Dose Interruptions
ParticipantsHS-10296Gefitinib
Number of Participants With Dose Interruptions3653
SecondaryNumber of Participants With Dose Reductions

Participants had at least one reduction in planned treatment dosage due to treatment emergent adverse events. Every participant took 2 pills of HS -10296 + 1 pill of placebo(experimental arm) or 2pills of placebo + 1pill of Gefitinib (control arm). When a dose reduction was decided by INV, the set of "2 pills of placebo" was decreased resulting in no reduction of active compound in control arm, compliance with dose modification for AEs in Gefitinib's label which includes interruption, discontinuation but reduction.

Time frame:
From baseline, then every 6 weeks, until disease progression or discontinuation from study. (up to 24 months)
Reported as:
Count of participants · Participants
Number of Participants With Dose Reductions
ParticipantsHS-10296Gefitinib
Number of Participants With Dose Reductions910

Adverse events

Collected over Serious and Other (Not Including Serious)Adverse Events (AEs) were collected from first dose of study drug up to 28days after last dose of study drug taken (up to data cut-off (15 Jan 2021)), approximately 2 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HS-1029654/214 (25.2%)47/214 (22%)211/214 (98.6%)
Gefitinib69/215 (32.1%)46/215 (21.4%)213/215 (99.1%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventHS-10296Gefitinib
Hepatic function abnormalHepatobiliary disorders2/2149/215
PneumoniaInfections and infestations6/2148/215
Increased alanine aminotransferaseInvestigations0/2144/215
Increased aspartate aminotransferaseInvestigations0/2144/215
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/2140/215
Venous thrombosis of extremitiesVascular disorders3/2140/215
PneumonitisRespiratory, thoracic and mediastinal disorders1/2143/215
Herpes zosterInfections and infestations2/2140/215
Cerebral infarctionNervous system disorders2/2140/215
HeadacheNervous system disorders2/2140/215
Most frequent other events
Showing 10 of 41
Most frequent other events
EventHS-10296Gefitinib
ErythraSkin and subcutaneous tissue disorders50/21489/215
Blood creatine phosphokinase increasedInvestigations76/21420/215
Platelet count decreasedInvestigations47/21417/215
AnemiaBlood and lymphatic system disorders43/21421/215
Upper respiratory infectionInfections and infestations41/21426/215
Weight lossInvestigations14/21435/215
Blood bilirubin increasedInvestigations18/21434/215
HypokalemiaMetabolism and nutrition disorders19/21433/215
γ-glutamyl transferase increasedInvestigations19/21430/215
Blood lactate dehydrogenase increasedInvestigations26/21414/215

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)HS-10296GefitinibTotal
<=18 years000
Between 18 and 65 years155139294
>=65 years5976135
Age, Continuous
Age, Continuous(years)HS-10296GefitinibTotal
Mean58.1 ± 9.5960.6 ± 9.7259.3 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)HS-10296GefitinibTotal
Female134135269
Male8080160
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HS-10296GefitinibTotal
American Indian or Alaska Native000
Asian214215429
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Smoking status
Smoking status(Participants)HS-10296GefitinibTotal
Never smoked156144300
smoked5871129
08

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, China
09

References and documents

Publications

  • Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. PubMed 35580297 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jan 2021, 23 months.

Results were first posted in Jan 2023, 2 years after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 23 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2018
First posted
Feb 21, 2019
StartActual
Feb 1, 2019
Primary completionActual
Jan 15, 2021
CompletionEst.
Jun 30, 2023
Results first posted
Jan 20, 2023
Last update
Jan 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03849768
Responsible party
Sponsor
First posted
Feb 21, 2019
Start date
Feb 1, 2019
Primary completion
Jan 15, 2021
Completion
Jun 30, 2023 (estimated)
Results posted
Jan 20, 2023
Last update
Jan 20, 2023

Study contacts

Maniam Ajit, MD
study chair · Pacific Cancer Medical Center, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion